UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1340-5
Program Prior Authorization/Notification
Medication Mycapssa® (octreotide)
P&T Approval Date 12/2020, 12/20021, 12/2022, 12/2023, 1/2024
Effective Date 4/1/2025
1. Background:
Mycapssa (octreotide) is a somatostatin analog indicated for long-term maintenance treatment in
acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
2. Coverage Criteriaa:
A. Acromegaly
1. Initial Authorization
a. Mycapssa will be approved based both of the following criteria:
(1) Diagnosis of acromegaly
-AND-
(2) Patient has responded to and tolerated treatment with one of the following
somatostatin analogs:
i. Sandostatin (octreotide) or Sandostatin LAR
ii. Somatuline Depot (lanreotide)
Authorization will be issued for 12 months.
2. Reauthorization
a. Mycapssa will be approved based on of the following criterion:
(1) Documentation of positive clinical response to Mycapssa therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• Medical Necessity may be in place.
4. References:
1. Mycapssa [package insert]. Scotland, UK: MW Encap Ltd.; August 2024.
Program Prior Authorization/Notification – Mycapssa® (octreotide)
Change Control
11/2020 New program
12/2021 Annual review with no change to clinical criteria.
12/2022 Annual review with no change to clinical criteria. Added state mandate
footnote and updated reference.
12/2023 Annual review with no change to clinical criteria.
1/2025 Annual review with no change to clinical criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2